Abstracts tagged "radiography"

Abstract Number: 1622 • 2015 ACR/ARHP Annual Meeting
Genome-Wide Association Analysis and Whole Genome Sequencing Identify Variants Associated with Radiographic Severity of Rheumatoid Arthritis in African Americans
Vincent A. Laufer¹, Richard J. Reynolds², Maria I. Danila³, R. Curtis Hendrickson⁴, Elliot J. Lefkowitz⁵, Devin Absher⁶, Robert P. Kimberly⁷ and S. Louis Bridges Jr.⁸, ¹Division of Clinical Rheumatology and Immunology, University of Alabama at Birmingham, Birmingham, AL, ²Medicine, University of Alabama at Birmingham, Birmingham, AL, ³AL, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Microbiology, University of Alabama at Birmingham, Birmingham, AL, ⁶Hudson Alpha Institute for Biotechnology, Huntsville, AL, ⁷Medicine, Clinical Immun & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁸Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Joint damage manifested by bony erosions and joint space narrowing is a major contributor to the morbidity and mortality of RA. Reports in Caucasians…
Abstract Number: 2812 • 2014 ACR/ARHP Annual Meeting
Is Rheumatoid Arthritis the Same Disease in Women and Men?- Joint Damage in Patients with EARLY Rheumatoid Arthritis at 10 YEARS after Diagnosis
Juha Asikainen¹, Kalevi Kaarela², Heidi Mäkinen³, Hannu Kautiainen⁴, Pekka Hannonen⁵, Tuomas Rannio⁶ and Tuulikki Sokka⁷, ¹Jyvaskyla Central Hospital, Jyväskylä, Finland, ²Jyväskylä Central Hospital, Jyväskylä, Finland, ³Tampere University Hospital, Tampere, Finland, ⁴Medcare Oy, Äänekoski, Finland, ⁵Jyväskylä Central Hospital, Jyvaskyla, Finland, ⁶Kuopio University Hospital, Kuopio, Finland, ⁷Jyvaskyla Central Hospital, Jyvaskyla, Finland
Background/Purpose: Rheumatoid arthritis (RA) is suggested to be a more severe disease in women than in men as disease activity appears higher in women, and…
Abstract Number: 2502 • 2014 ACR/ARHP Annual Meeting
Ten Year Follow-up Results of Four Dynamic Treat to Target Strategies in Patients with ACPA Negative Rheumatoid Arthritis
I.M. Markusse¹, G. Akdemir², L. Dirven², M. van den Broek², K.H. Han³, H.K Ronday⁴, P.J.S.M. Kerstens⁵, W.F. Lems^6,7, T.W.J. Huizinga² and C.F. Allaart², ¹Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology, MCRZ hospital, Rotterdam, Netherlands, ⁴Rheumatology, Haga Hospital, The Hague, Netherlands, ⁵Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁶Rheumatology, VU Medical Center, Amsterdam, Netherlands, ⁷Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands
Background/Purpose: To determine the optimal treatment strategy in patients with anti-citrullinated protein antibodies (ACPA) negative (‒) rheumatoid arthritis (RA), as it has been suggested that…
Abstract Number: 2028 • 2014 ACR/ARHP Annual Meeting
Effect of Age at Rheumatoid Arthritis Onset on Clinical, Radiographic, and Functional Outcomes: The Espoir Cohort
Thomas Krams¹, Adeline Ruyssen-Witrand², Delphine Nigon¹, Bruno Fautrel^3,4,5, Francis Berenbaum^6,7, Alain G. Cantagrel⁸ and Arnaud Constantin⁹, ¹Rhumatologie, Purpan University Hospital, Toulouse, France, ²Rheumatology, Purpan University Hospital, Toulouse, France, ³Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France, ⁴Rheumatology, UPMC GRC08, Paris 06 University, Pitié Salpétrière Hospital, Paris, France, ⁵Rheumatology, Pitie Salpetriere Hospital, Paris, France, ⁶Service de Rhumatologie, Saint-Antoine Hospital, Paris, France, ⁷INSERM - UMR S 938, Paris, France, ⁸Rheumatology, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France, ⁹Rheumatology, Purpan University Hospital, Toulouse Cedex 9, France
Background/Purpose: Rheumatoid arthritis (RA) is a chronic disease with peak incidence in the fourth and fifth decades of age. To investigate whether age at disease…
Abstract Number: 1386 • 2014 ACR/ARHP Annual Meeting
Disease Flares during 10 Year Follow-up in Patients with Rheumatoid Arthritis Are Associated with Joint Damage Progression and Disability
I.M. Markusse¹, L. Dirven², Y.P. Goekoop-Ruiterman³, P.a. van der Lubbe⁴, A.J. Peeters⁵, P.J.S.M. Kerstens⁶, W.F. Lems^7,8, T.W.J. Huizinga² and C.F. Allaart², ¹Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology, HAGA hospital, The Hague, Netherlands, ⁴Rheumatology, Vlietland Hospital, Schiedam, Netherlands, ⁵Rheumatology, Reinier de Graaf Gasthuis, Delft, Netherlands, ⁶Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁷Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁸Rheumatology, VU Medical Center, Amsterdam, Netherlands
Background/Purpose: Disease flares frequently occur in patients with rheumatoid arthritis (RA). It has been suggested that these may spontaneously remit, in which case targeted treatment…
Abstract Number: 184 • 2014 ACR/ARHP Annual Meeting
Ultrasound Versus X-Rays Versus Synovial Fluid Analysis for the Diagnosis of Calcium Pyrophosphate Dihydrate Deposition Disease: Is It CPPD?
Georgios Filippou¹, Antonella Adinolfi¹, Sauro Lorenzini², Ilaria Bertoldi¹, Valentina Di Sabatino¹, Valentina Picerno¹, Luca Sconfienza³, Mauro Galeazzi¹ and Bruno Frediani¹, ¹University of Siena, Siena, Italy, ²Clinical medicine and Immunological science, Rheumatology Unit, Azienda Ospedaliera Universitaria Senese, Siena, Italy, ³University of Milan, Milan, Italy
Background/Purpose: The diagnosis of calcium pyrophosphate crystal (CPP) deposition disease (CPPD) is mainly based on the synovial fluid analysis and Xrays. US has demonstrated high…
Abstract Number: 1977 • 2013 ACR/ARHP Annual Meeting
Remission At 3 Or 6 Months and Radiographic Non-Progression At 12 Months In Methotrexate-Naïve Rheumatoid Arthritis Patients Treated With Tofacitinib Or Methotrexate: A Post-Hoc Analysis Of The ORAL Start Trial
V. Strand¹, D. van der Heijde², R. Landewe³, E. B. Lee⁴, B. Wilkinson⁵, S. H. Zwillich⁵, J. Bradley⁵, C. Mebus⁵, B. Benda⁶ and D. Gruben⁵, ¹Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ⁴Seoul National University, Seoul, South Korea, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is a novel, oral Janus kinase (JAK) inhibitor for the treatment of RA. The importance of “treat to target” in RA to attain…
Abstract Number: 1978 • 2013 ACR/ARHP Annual Meeting
The Effect Of Certolizumab On Lymphatic Volume and Flow In Rheumatoid Arthritis Patients With Acute Flare
Homaira Rahimi¹, Vaseem Chengazi², Gregory Dieudonne², Edward M. Schwarz³ and Christopher T. Ritchlin⁴, ¹Pediatrics, University of Rochester, Rochester, NY, ²Radiology, University of Rochester, Rochester, NY, ³Center for Musculoskeletal Research, University of Rochester, Rochester, NY, ⁴Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY
Background/Purpose: Episodic flare occurs in rheumatoid arthritis (RA) but the mechanisms of this process are not well understood. Our prior reports on MRI analysis of…
Abstract Number: 1965 • 2013 ACR/ARHP Annual Meeting
Performance Of a Computer-Based Method To Measure Erosions In Rheumatoid Arthritis: A Longitudinal Study
Jeremy Wortman¹, Stacy Smith¹, Frederick Wolfe² and Jeffrey W. Duryea¹, ¹Radiology, Brigham and Women's Hospital, Boston, MA, ²National Data Bank for Rheumatic Diseases, Wichita, KS
Background/Purpose: To describe the methodology of a novel computer-based technique for outlining erosions on plain radiographs in rheumatoid arthritis (RA) patients, and assess the responsiveness…
Abstract Number: 1788 • 2013 ACR/ARHP Annual Meeting
The Multi-Biomarker Disease Activity Test (Vectra^® DA) Estimates Risk Of Radiographic Progression For Patients With Rheumatoid Arthritis From The Leiden Early Arthritis Clinic
Wanying Li¹, DJ Haney¹, Guy Cavet¹, Thomas W. Huizinga², Eric H. Sasso¹ and A. H. M. van der Helm-van Mil³, ¹Crescendo Bioscience Inc., South San Francisco, CA, ²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The multi-biomarker disease activity (MBDA) blood test assesses disease activity in patients with rheumatoid arthritis (RA) using a validated algorithm to provide a score…
Abstract Number: 1348 • 2013 ACR/ARHP Annual Meeting
Initial Combination Therapy In Early Rheumatoid Arthritis: Which Patients Benefit?
I.M. Markusse¹, K.H. Han², A.J. Peeters³, H.K Ronday⁴, P.J.S.M. Kerstens⁵, T.W.J. Huizinga¹, W.F. Lems⁶ and C.F. Allaart¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ³Rheumatology, Reinier de Graaf Gasthuis, Delft, Netherlands, ⁴Rheumatology, Haga Hospital, The Hague, Netherlands, ⁵Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁶Rheumatology, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Initial combination therapy has proven to be effective in early rheumatoid arthritis (RA) patients. To determine which patients benefit from initial combination therapy. Methods:…
Abstract Number: 1322 • 2013 ACR/ARHP Annual Meeting
Osteoprotegerin and TNF-Related Apoptosis Inducing Ligand Are Respectively Predictive Factors Of Remission and Erosion In Early Rheumatoid Arthritis Patients Included In The French Cohort Espoir
Rachel Audo¹, Laura Papon¹, Claire I. Daien^1,2, Cédric Lukas³, Bernard Combe², Olivier Vittecoq⁴, Michael Hahne¹ and Jacques Morel⁵, ¹IGMM, CNRS UMR5535, Montpellier, Montpellier, France, ²Department of Rheumatology, Lapeyronie Hospital, Montpellier, France, ³Immuno-Rhumatologie, Hopital Lapeyronie, Montpellier, France, ⁴Rheumatology, Rouen University Hospital & Inserm905, University of Rouen, Rouen Cedex, France, ⁵Dpartment of Rheumatology, Lapeyronie Hospital, Montpellier, France
Background/Purpose: TNF-Related Apoptosis Inducing Ligand (TRAIL) is a member of the TNF familly. Its soluble receptor Osteoprotegerin (OPG) also inhibits Receptor activator of nuclear factor…
Abstract Number: 1311 • 2013 ACR/ARHP Annual Meeting
Aiming Simple Disease Activity Score Remission At One Year Leads To Better 3-Year Radiographic and Functional Outcomes Than aiming low Disease activity in Early Rheumatoid Arthritis Patients Treated In Routine Practice. Data From Espoir Cohort
Adeline Ruyssen-Witrand¹, Gregory Guernec², Delphine Nigon³, Gabriel Tobon⁴, Bénédicte Jamard⁵, Anne-Christine Rat⁶, Olivier Vittecoq⁷, Alain G. Cantagrel⁸ and Arnaud L. Constantin¹, ¹Rheumatology, Purpan University Hospital, Toulouse, France, ²UMR 1027, Inserm, Toulouse, France, ³Rheumatology, CHU Purpan - Hôpital Pierre-Paul Riquet, Toulouse, France, ⁴Unit of immunology, Brest, France, ⁵Toulouse University Hospital, Toulouse, France, ⁶Université de Lorraine, Nancy, F-54000, France; Inserm, CIC-EC CIE6, Nancy, F-54000, France; CHU de Nancy, Clinical Epidemiology and Evaluation Department, Nancy, F-54000, France; CHU de Nancy, Rheumatology department, Nancy, France, ⁷Rheumatology, Rouen University Hospital & Inserm905, University of Rouen, Rouen Cedex, France, ⁸Centre Hospitalier Universitaire de Toulouse, Toulouse, France
Background/Purpose: The ultimate goal of Disease Modifying Anti-Rheumatic Drugs (DMARDs) treatment in early rheumatoid arthritis (RA) is to achieve remission in order to prevent structural…
Abstract Number: 1116 • 2013 ACR/ARHP Annual Meeting
A Prospective Evaluation Of The Diagnostic Value Of Conventional Radiography, Ultrasound and MRI In Comparison To Clinical Examination For The Assessment Of Heel and Knee Enthesitis In Patients With Peripheral Spondyloarthritis and Controls
Xenofon Baraliakos¹, Uta Kiltz², Frank Heldmann³, Heiner Appel⁴, Friedrich Dybowski⁵, Manfred Igelmann⁶, Ludwig H. Kalthoff⁷, Claudia Klink⁸, Dietmar MJ Krause⁹, Ertan Saracbasi³, Elmar Schmitz-Bortz¹⁰ and Jürgen Braun³, ¹Rheumatology, Rheumazentrum Ruhrgebiet, Herne, Germany, ²Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, ³Rheumazentrum Ruhrgebiet, Herne, Germany, ⁴Rheumatology and Nephrology Practice, Hamm, Germany, ⁵Rheumatology Practice, Herne, Germany, ⁶Private Rheumatology office, Bochum, Germany, ⁷Private rheumatology office, Herne, Germany, ⁸Private rheumatology office, Gladbeck, Germany, ⁹Internistische und rheumatologische Gemeinschaftspraxis, Gladbeck, Germany, ¹⁰Rheumatology practice, Hattingen, Germany
Background/Purpose: Spondyloarthritides (SpA) are characterized by inflammatory and structural changes in the axial skeleton and in peripheral joints and entheses. Imaging has an essential role…
Abstract Number: 2670 • 2012 ACR/ARHP Annual Meeting
Genome-Wide Association Study On the Severity of Joint Destruction in Autoantibody Positive Rheumatoid Arthritis Identifies a Role for Sperm Associated Antigen 16
Rachel Knevel¹, Kerstin Klein², Klaartje Somers³, Caroline Ospelt⁴, Jeanine J. Houwing-Duistermaat⁵, Jessica van Nies⁶, Diederik P.C. de Rooy⁶, Laura de Bock⁷, Joris Schonkeren⁸, Gerrie Stoeken-Rijsbergen⁶, Jenna Kiridly⁹, Luis Rodriguez-Rodriguez⁹, Quinta Helmer⁵, Piet Sinissen³, Tom W. J. Huizinga¹, René E.M. Toes¹, Steffen Gay¹⁰, Peter K. Gregersen¹¹, Veerle Somers⁷ and Annette H.M. van der Helm - van Mil⁸, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP),, Zurich, Switzerland, ³Hasselt University, Biomedical Research Institute, Diepenbeek, Belgium, ⁴Center of Experimental Rheumatology, University Hospital Zurich and Zurich Center of Integrative Human Physiology (ZIHP), Switzerland, Zurich, Switzerland, ⁵Department of Medical Statistics and Bioinformatics, Leiden, Netherlands, ⁶Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁷Hasselt University, Biomedical Research Institute, Belgium, ⁸Leiden University Medical Center, Leiden, Netherlands, ⁹Feinstein Institute for Medical Research and North Shore–Long Island Jewish Health System, Manhasset, New York, ¹⁰Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland, ¹¹Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: Recent genome-wide association studies (GWAs) have identified >30 SNPs predisposing to Rheumatoid Arthritis (RA). These variants are helpful in unraveling the pathogenesis of RA.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].